Related Experiment Video
Updated: Feb 26, 2026
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
Role of mpMRI of the prostate in screening for prostate cancer
Christopher J D Wallis1,2, Masoom A Haider3, Robert K Nam1,2
1Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada.
Abstract:
Prostate cancer screening offers the opportunity to significantly reduce morbidity and mortality from this disease. Currently, serum prostate-specific antigen (PSA) testing is the most widely used screening modality. However, PSA testing continues to have low positive and negative predictive value leading to unnecessary invasive prostate biopsy while missing patients with aggressive forms of the disease. Magnetic resonance imaging (MRI) has been gaining an increasingly large role in the management of patients with early stage prostate cancer including diagnosis in patients with abnormal PSA levels, monitoring of patients on active surveillance, and staging prior to definitive interventions. MRI-based prostate cancer risk assessment has been shown to better distinguish between clinically-significant and insignificant tumors than PSA testing alone or from nomograms. Preliminary data indicate that, among unselected patients, MRI outperforms PSA in the identification of patients with clinically significant prostate cancer. Further work is needed to examine the role of mpMRI in prostate cancer screening.
Insights
Prostate cancer screening can reduce disease mortality. Magnetic resonance imaging (MRI) shows promise in identifying aggressive prostate cancer, potentially outperforming prostate-specific antigen (PSA) testing.
Area of Science:
- Urology
- Radiology
- Oncology
Background:
- Serum prostate-specific antigen (PSA) testing is the primary method for prostate cancer screening.
- PSA testing has limitations, including low predictive value, leading to unnecessary biopsies and missed aggressive cancers.
Purpose of the Study:
- To evaluate the role of Magnetic Resonance Imaging (MRI) in prostate cancer risk assessment.
- To compare the efficacy of MRI-based assessment versus PSA testing in identifying clinically significant prostate cancer.
Main Methods:
- Review of current literature on MRI applications in prostate cancer management.
- Analysis of preliminary data comparing MRI performance to PSA testing and nomograms.
Main Results:
- MRI-based risk assessment demonstrates superior ability to differentiate significant from insignificant tumors compared to PSA alone or nomograms.
- Preliminary findings suggest MRI outperforms PSA in identifying clinically significant prostate cancer in unselected populations.
Conclusions:
- MRI is increasingly valuable in diagnosing, monitoring, and staging prostate cancer.
- Further research is required to establish the role of multiparametric MRI (mpMRI) in population-based prostate cancer screening.
Related Concept Videos
01:27Imaging Studies IV: Magnetic Resonance Imaging
01:24Magnetic Resonance Imaging
01:33Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...